Showing results (1-10 of 199) with videos related to
Sort By:
Pageof 20
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2017
Is Disease-Specific Immunotherapy a Potential Reality for MDS?David A Sallman, Marco L DavilaActa Haematologica|December 5, 2023
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future ConsiderationsJeremy DiGennaro, David A SallmanClinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular CharacterizationDavid A Sallman, Eric PadronHematology/Oncology and Stem Cell Therapy|May 18, 2016
Integrating mutation variant allele frequency into clinical practice in myeloid malignanciesDavid A Sallman, Eric PadronBlood|January 24, 2019
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromesDavid A Sallman, Alan ListCurrent Opinion in Hematology|December 2, 2021
Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignanciesChen Wang, David A SallmanCancer Journal (Sudbury, Mass.)|January 24, 2022
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?Chen Wang, David A SallmanCurrent Treatment Options in Oncology|March 25, 2023
Current Therapeutic Landscape in Lower Risk Myelodysplastic SyndromesChen Wang, David A SallmanBlood|September 5, 2024
TP53-mutated acute myeloid leukemia: how can we improve outcomes?David A Sallman, Maximilian StahlLeukemia & Lymphoma|November 26, 2022
Therapeutic approaches for the management of higher risk myelodysplastic syndromesChen Wang, David A SallmanPageof 20